

Don't risk shingles^{1,2}

Prevention starts with an informed conversation

If you're 50 years or older, the risk of getting this painful, blistering rash is very real^{1,3} – no matter how healthy you may feel. Vaccination is the only way to help protect yourself from shingles^{*4}. Use this guide at your next doctor's appointment to learn if SHINGRIX is right for you.

*Vaccination with SHINGRIX may not fully protect all vaccine recipients²

QUICK FACTS:

Shingles is caused by the reactivation of the varicella zoster virus, the same virus that causes chickenpox.^{1,5}



Over 90% of adults 50 years and older may already carry the virus.^{1,6,8}



Shingles can lead to painful and long-term complications.^{1,5}



1 in 3 adults will get shingles[†]... the pain can be severe at any age.^{1,7,9}



[†]US data, may not be representative of the New Zealand population.

Shingles and its complications can disrupt your life for weeks, months, or even years.¹



SHINGRIX
RECOMBINANT VARICELLA ZOSTER
VIRUS GLYCOPROTEIN E VACCINE





SHINGRIX
RECOMBINANT VARICELLA ZOSTER
VIRUS GLYCOPROTEIN E VACCINE



Don't risk shingles^{1,2}

Get the conversation started

Here are some **questions to guide your discussion:**

1

I am over 50 but feel healthy and try to stay fit. **Am I still at risk for shingles?**

2

People talk about the terrible impact shingles pain has had on their lives. **Is it that painful?**

3

Can you **tell me more** about the potential **long-term complications of shingles?**

4

If I haven't had chickenpox, **can I get shingles?**

5

I've had shingles before. **Can I get it again?**

No matter how healthy or young you may feel, shingles can happen at anytime.^{1,3,5}

Talk to your pharmacist, doctor or nurse about vaccination with SHINGRIX.

As with any vaccine, a protective immune response may not be elicited in all vaccinees.²

Side effects that may occur after receiving SHINGRIX: pain, redness and swelling at the injection site, headache, muscle pain and tiredness. This is not a full list.²



Images are for illustrative purposes only.

References: 1.Harpaz: 2008 Jun 6;57:1-30. 2.GSK NZ, SHINGRIX Data Sheet, 2025. 3.Kawai K, et al. BMJ Open. 2014 Jun;4(6):e004833. 4.CDC;2024;1-3;Shingles Vaccination. 5.Te Whatu Ora Immunisation Handbook 2025:v4;Chapter 25. 6.Kilgore PE;Journal of medical virology;2003;70;S111-8. 7. Katz J;Surgical Clinics of North America;1999;79;231-252. 8. Bollaerts K;Epidemiology and Infection;2017;145;2666-2677. 9. WHO;2025;1-5;Shingles (herpes zoster)

SHINGRIX (Recombinant Varicella Zoster Virus Glycoprotein E antigen 50 mcg (AS01₃ adjuvanted vaccine)) is indicated for the prevention of herpes zoster and post-herpetic neuralgia in adults 50 years of age or older and for adults 18 years of age or older who are at increased risk of herpes zoster. **SHINGRIX, a prescription medicine, is funded for people aged 65 years. From 1 July 2024, SHINGRIX is also funded for certain individuals 18 years and over at higher risk of shingles. See full funding criteria at pharmac.govt.nz. Costs will apply if SHINGRIX is not funded.** A single 0.5 mL dose contains 50 mcg of gE antigen, adjuvanted with AS01₃ (composed of the plant extract *Quillaja saponaria* saponin (QS-21) (50 mcg) and 3-O-desacetyl-4'-monophosphoryl lipid A (MPL) from *Salmonella minnesota* (50 mcg) plus excipients). **SHINGRIX should not be administered if you are hypersensitive to any component of this vaccine. SHINGRIX has risks and benefits – ask your doctor if SHINGRIX is right for you. Use strictly as directed. Normal doctor's charges apply. Side effects:** Adults ≥50 years: pain, redness and swelling at the injection site, muscle pain, fatigue, headache, shivering, fever, and gastrointestinal symptoms. Adults at increased risk of shingles between the ages of 18 to 49 years are more likely to experience side effects such as pain at the injection site, fatigue, muscle pain, headache, shivering and fever compared to those aged ≥50 years. This is not a full list. Vaccination with SHINGRIX may not protect all vaccine recipients. If you have side effects, see your doctor, pharmacist or healthcare professional. **Additional product information and Consumer Medicine Information (CMI) is available at www.medsafe.govt.nz.** Trademarks are owned by or licensed to the GSK group of companies. ©2025 GSK group of companies or its licensor. Marketed by GlaxoSmithKline NZ Ltd, Auckland. **Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500. TAPS NP23352 PM-NZ-SGX-PINF-240001 Date of Approval: 09 2025 Date of Expiry: 09 2027**